Cybin (OTCMKTS:CYBN) Stock Price Up 4,086.3%

Cybin Inc. (OTCMKTS:CYBN)’s stock price rose 4,086.3% during mid-day trading on Thursday . The stock traded as high as $8.55 and last traded at $8.54. Approximately 570,897 shares changed hands during mid-day trading, an increase of 335% from the average daily volume of 131,147 shares. The stock had previously closed at $0.20.

Cybin Price Performance

The business’s 50 day simple moving average is $0.26 and its 200 day simple moving average is $0.32. The stock has a market cap of $3.51 billion, a P/E ratio of -42.70 and a beta of 0.42.

Cybin (OTCMKTS:CYBN) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.01) EPS for the quarter. Research analysts predict that Cybin Inc. will post -0.19 earnings per share for the current year.

Institutional Trading of Cybin

A hedge fund recently bought a new stake in Cybin stock. Rosalind Advisors Inc. acquired a new position in Cybin Inc. (OTCMKTS:CYBN) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 13,960,000 shares of the company’s stock, valued at approximately $5,772,000. Cybin comprises approximately 5.4% of Rosalind Advisors Inc.’s investment portfolio, making the stock its 7th largest position. Rosalind Advisors Inc. owned 3.40% of Cybin as of its most recent SEC filing. Institutional investors own 17.94% of the company’s stock.

About Cybin

Cybin Inc, a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation.